BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 22388737)

  • 1. Topoisomerase I poisoning results in PARP-mediated replication fork reversal.
    Ray Chaudhuri A; Hashimoto Y; Herrador R; Neelsen KJ; Fachinetti D; Bermejo R; Cocito A; Costanzo V; Lopes M
    Nat Struct Mol Biol; 2012 Mar; 19(4):417-23. PubMed ID: 22388737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition.
    Berti M; Ray Chaudhuri A; Thangavel S; Gomathinayagam S; Kenig S; Vujanovic M; Odreman F; Glatter T; Graziano S; Mendoza-Maldonado R; Marino F; Lucic B; Biasin V; Gstaiger M; Aebersold R; Sidorova JM; Monnat RJ; Lopes M; Vindigni A
    Nat Struct Mol Biol; 2013 Mar; 20(3):347-54. PubMed ID: 23396353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
    Tomicic MT; Kaina B
    Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
    Znojek P; Willmore E; Curtin NJ
    Br J Cancer; 2014 Sep; 111(7):1319-26. PubMed ID: 25003660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tipin functions in the protection against topoisomerase I inhibitor.
    Hosono Y; Abe T; Higuchi M; Kajii K; Sakuraba S; Tada S; Enomoto T; Seki M
    J Biol Chem; 2014 Apr; 289(16):11374-11384. PubMed ID: 24573676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin.
    Park SY; Cheng YC
    Cancer Res; 2005 May; 65(9):3894-902. PubMed ID: 15867389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
    D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
    Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATP modulates poly(ADP-ribose) polymerase-1-facilitated topoisomerase I-linked DNA religation in the presence of camptothecin.
    Park SY; Leung CH; Cheng YC
    Mol Pharmacol; 2008 Jun; 73(6):1829-37. PubMed ID: 18349103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
    Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
    Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage.
    Vance JR; Wilson TE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13669-74. PubMed ID: 12368472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes.
    Regairaz M; Zhang YW; Fu H; Agama KK; Tata N; Agrawal S; Aladjem MI; Pommier Y
    J Cell Biol; 2011 Nov; 195(5):739-49. PubMed ID: 22123861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae.
    Sloan R; Huang SN; Pommier Y; Jinks-Robertson S
    DNA Repair (Amst); 2017 Nov; 59():69-75. PubMed ID: 28961461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pold4 subunit of replicative polymerase δ promotes fork slowing at broken templates.
    Kojima K; Ohkubo H; Kawasumi R; Hirota K
    DNA Repair (Amst); 2024 Jul; 139():103688. PubMed ID: 38678695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.
    Xu Y; Her C
    Biomolecules; 2015 Jul; 5(3):1652-70. PubMed ID: 26287259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA.
    Sugimura K; Takebayashi S; Taguchi H; Takeda S; Okumura K
    J Cell Biol; 2008 Dec; 183(7):1203-12. PubMed ID: 19103807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
    Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1.
    El-Khamisy SF; Saifi GM; Weinfeld M; Johansson F; Helleday T; Lupski JR; Caldecott KW
    Nature; 2005 Mar; 434(7029):108-13. PubMed ID: 15744309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.
    Adachi N; So S; Koyama H
    J Biol Chem; 2004 Sep; 279(36):37343-8. PubMed ID: 15218034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.